Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | APEX1 | P27695 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1101353 | 0.92 | THRB (0.55) | THRBTSHRALDH1A1POLBAPEX1 | |
| SCHEMBL4536017 | 0.85 | THRB (0.48) | THRBTSHRALDH1A1POLBAPEX1 | |
| SCHEMBL19772746 | 0.84 | THRB (0.52) | THRBTSHRALDH1A1POLBAPEX1 | |
| SCHEMBL4294879 | 0.83 | THRB (0.47) | THRBTSHRALDH1A1POLBAPEX1 | |
| SCHEMBL16441931 | 0.82 | THRB (0.50) | THRBTSHRALDH1A1POLBAPEX1 | |
| SCHEMBL13400212 | 0.81 | TSHR (0.48) | THRBTSHRALDH1A1POLBAPEX1 | |
| SCHEMBL6118126 | 0.81 | THRB (0.57) | THRBTSHRALDH1A1POLBAPEX1 | |
| SCHEMBL29144863 | 0.80 | TSHR (0.46) | THRBTSHRALDH1A1POLBAPEX1 | |
| SCHEMBL212008 | 0.79 | THRB (0.55) | THRBTSHRALDH1A1POLBAPEX1 | |
| SCHEMBL1040128 | 0.79 | ALDH1A1 (0.43) | TSHRALDH1A1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108785687-A | A kind of preparation method of the synergistic antitumor polymeric prodrugs of more stimuli responsives | 西南大学 | 2018-11-13 | — | — | CN | claimed |
| US-20190076467-A1 | ANTIVIRAL CONJUGATES OF POLYANIONIC POLYMER AND ANTIVIRAL DRUG | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2019-03-14 | — | — | US | disclosed |
| CN-108785687-A | A kind of preparation method of the synergistic antitumor polymeric prodrugs of more stimuli responsives | 西南大学 | 2018-11-13 | — | — | CN | disclosed |
| WO-2016025747-A1 | NONLINEAR COPOLYMERS AS INTRACELLULAR DELIVERY VEHICLES AND RELATED METHODS | STAYTON PATRICK S (US) | 2016-02-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190076467-A1 | ANTIVIRAL CONJUGATES OF POLYANIONIC POLYMER AND ANTIVIRAL DRUG | SARS1, EIF2AK2, TLR3 | THRB 4794/4885TSHR 4655/4885ALDH1A1 3508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.